open access

Vol 70, No 6 (2020)
Research paper (original)
Published online: 2020-12-04
Get Citation

Breast-conserving surgeries in HER-positive breast cancer patients are performed too rarely in Poland

Joanna Kufel-Grabowska, Barbara Radecka, Joanna Streb, Agnieszka Jagiełło-Gruszfeld, Joanna Hudała-Klecha, Ewa Szombara, Renata Sienkiewicz, Bogumiła Czartoryska-Arłukowicz, Piotr Witasik, Katarzyna Sokołowska, Wojciech Wysocki
DOI: 10.5603/NJO.2020.0047
·
Nowotwory. Journal of Oncology 2020;70(6):225-229.

open access

Vol 70, No 6 (2020)
Original article
Published online: 2020-12-04

Abstract

Breast cancer is the most common cancer among women in Poland and worldwide; after lung cancer it is the second highest cause of death among females with malignancies. HER2 positive breast cancer occurs in ca.15–20% of all cases. More often than other subtypes, it affects younger patients and more often spreads metastasises to internal organs.

The new drugs against the HER2 receptor significantly improve patients’ prognoses, regardless of the initial stage. The authors of the study involved 1503 patients with HER2 positive breast cancer from all stages (I–IV); 482 patients received preoperative systemic therapy (chemotherapy or hormonal therapy), 385 trastuzumab. Among the 1219 females qualified to surgery, 734 (60%) underwent a mastectomy, 485 (40%) had breast conserving therapy with adjuvant radiotherapy, some of them had preoperative systemic treatment.

Abstract

Breast cancer is the most common cancer among women in Poland and worldwide; after lung cancer it is the second highest cause of death among females with malignancies. HER2 positive breast cancer occurs in ca.15–20% of all cases. More often than other subtypes, it affects younger patients and more often spreads metastasises to internal organs.

The new drugs against the HER2 receptor significantly improve patients’ prognoses, regardless of the initial stage. The authors of the study involved 1503 patients with HER2 positive breast cancer from all stages (I–IV); 482 patients received preoperative systemic therapy (chemotherapy or hormonal therapy), 385 trastuzumab. Among the 1219 females qualified to surgery, 734 (60%) underwent a mastectomy, 485 (40%) had breast conserving therapy with adjuvant radiotherapy, some of them had preoperative systemic treatment.

Get Citation

Keywords

breast cancer; HER2 positive breast cancer; surgery; mastectomy; breast conserving therapy

About this article
Title

Breast-conserving surgeries in HER-positive breast cancer patients are performed too rarely in Poland

Journal

Nowotwory. Journal of Oncology

Issue

Vol 70, No 6 (2020)

Article type

Research paper (original)

Pages

225-229

Published online

2020-12-04

DOI

10.5603/NJO.2020.0047

Bibliographic record

Nowotwory. Journal of Oncology 2020;70(6):225-229.

Keywords

breast cancer
HER2 positive breast cancer
surgery
mastectomy
breast conserving therapy

Authors

Joanna Kufel-Grabowska
Barbara Radecka
Joanna Streb
Agnieszka Jagiełło-Gruszfeld
Joanna Hudała-Klecha
Ewa Szombara
Renata Sienkiewicz
Bogumiła Czartoryska-Arłukowicz
Piotr Witasik
Katarzyna Sokołowska
Wojciech Wysocki

References (10)
  1. Tao Z, Shi A, Lu C, et al. Breast Cancer: Epidemiology and Etiology. Cell Biochem Biophys. 2014; 72(2): 333–338.
  2. Cronin KA, Harlan LC, Dodd KW, et al. Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US. Cancer Invest. 2010; 28(9): 963–968.
  3. Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016; 17(6): 791–800.
  4. PTBR Sm, Mikułowska M, Komorowska A, Falkiewicz B. Gryglewicz J. Rak piersi w Polsce – leczenie to inwestycja. Sequence, Uczelnia Łazarskiego, Warszawa 2014.
  5. Tan MP. Is there an Ideal Breast Conservation Rate for the Treatment of Breast Cancer? Ann Surg Oncol. 2016; 23(9): 2825–2831.
  6. Cardoso F, Kyriakides S, Ohno S, et al. ESMO Guidelines Committee. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019; 30(10): 1674.
  7. Salindera S, Ogilvy M, Spillane A. What are the appropriate thresholds for High Quality Performance Indicators for breast surgery in Australia and New Zealand? Breast. 2020; 51: 94–101.
  8. Herman K, Śliwczyński A, Wysocki W. Wyniki, metody i koszty leczenia raka piersi w Polsce (w latach 2005–2007). Nowotwory. Journal of Oncology. 2014; 64(1): 33–39.
  9. Valachis A, Mauri D, Polyzos NP, et al. Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis. Breast. 2011; 20(6): 485–490.
  10. Mamtani A, Morrow M. Why Are There So Many Mastectomies in the United States? Annu Rev Med. 2017; 68: 229–241.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media sp. z o.o. VM Group sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl